Completed NA INTERVENTIONAL 2-arm NCT01176383

Impact of a Gene Test for Susceptibility to Lung Cancer in Smokers

A Protocol for an Randomised Controlled Trial of Smoking Cessation Success Rate With or Without a Genetic Test, Respiragene, to Assess Lung Cancer Risk - an Exploratory Study

Sponsor: Lab 21, Cambridge

Conditions Smoking Cessation

Interventions Respiragene test and risk score

Updated 5 times since 2017 Last updated: May 13, 2014 Started: Sep 30, 2011 Primary completion: Feb 28, 2013 Completion: Mar 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01176383, this NA trial focuses on Smoking Cessation and remains completed. Sponsored by Lab 21, Cambridge, it has been updated 5 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Lab 21, Cambridge
NHS Research and Development
Sussex NHS Research Consortium
University of Surrey

Data source: Sussex NHS Research Consortium

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Epsom, United Kingdom